Medical technology giant Medtronic, which has a large presence in North Haven, has won regulatory approval for a device to treat patients with a common heart rhythm disorder.
The device was approved for patients with recurrent atrial fibrillation (AF) that has not responded to drugs.
The company said its DiamondTemp Ablation (DTA) system is the first Food and Drug Administration-approved, temperature-controlled irrigated radiofrequency ablation system with diamonds.
Ablation is a minimally invasive procedure to treat AF, using radiofrequency energy to create scar tissue to interrupt irregular signals in the heart.
Medtronic said its ablation system includes a catheter embedded with industrial-grade diamonds, which have 200-400 times greater thermal conductivity when compared to conventional catheter materials.
The Dublin-based company said this provides “improved efficiencies” for surgeons, including faster procedure times. The system also delivers real-time feedback to help guide them as they create the scar tissue, Medtronic said.
Medtronic acquired the device as part of its 2019 acquisition of EPIX Therapeutics.
Contact Natalie Missakian at news@newhavenbiz.com
